Hepatocellular Carcinoma
Conditions
Brief summary
The main objective of this work is to evaluate the prevalence and results of specific management of HCC after spontaneous rupture, since the arrival of sorafenib in 2008.
Detailed description
Retrospective, observational, multicenter study over the period from January 2008 to April 2024. Cases had to be 18 years or older. They were identified by two different methodologies adapted to the 4 participating centers. In particular, a request for ICD10 C22.0 (CHC) codes associated with K66.1 (hemoperitoneum) was carried out by the medical information departments (DIM) of the Caen University Hospital and the Avicenne hospital. Secondly, the automated keyword selection tools Cohort 360 and i2b2 were used at the La Pitié Salpetrière and Paul Brousse hospital centers to identify the terms CHC and ruptured in the computerized patient files. Secondarily, duplicates and coding errors were excluded.
Interventions
None listed
Sponsors
University Hospital, Caen
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Ruptured hepatocellular carcinoma with or without cirrhosis
Exclusion criteria
* Liver adenoma without histologically proven HCC * Other benign or malignant liver tumors * ATCD of potentially triggering interventional procedure in the previous month. * Hemorrhagic ascites without tumor * Intratumoral hemorrhages without hemoperitoneum or capsular rupture
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival after rupture of hepatocellular carcinoma | 15 years |
Outcome results
None listed